Table 1 Description of Clinseq-AML cohort
From: Expression levels of long non-coding RNAs are prognostic for AML outcome
Number of patients | 274 |
Sex: no. of patients (%) | |
Male | 133 (48.5%) |
Female | 141 (51.4%) |
Age | |
Median (range) | 64.5 (18–85) |
No. of the patients aged < 60 | 109 (39.7%) |
Etiology | |
De novo AML | 222 |
s-AML | 24 |
t-AML | 26 |
Missing | 2 |
Median follow-up (days) | 346.5 |
Bone marrow blast: median (range, %) | 53.5% (14–100%) |
WBC counts: median (range, per mm3) | 20.5 (0.5–298.4) |
ELN | |
High | 53 |
Intermediate | 142 |
Low | 73 |
Cytogenetic aberrations: N (%) | |
t(15;17) | 8 (2.9%) |
t(8;21) | 5 (1.8%) |
inv(16)/t(16;16) | 9 (3.3%) |
Normal | 130 (47.4%) |
inv(3)/t(3;3) | 5 (1.8%) |
Complex | 32 (11.7%) |
del(5) | 17 (6.2%) |
del(7) | 27 (9.9%) |
t(11q23) | 7 (2.6%) |
Mutation: N (%) | |
ASXL1 | 28 (10.22%) |
CEBPA | 39 (14.23%) |
CEBPA (double) | 17 (6.2%) |
DNMT3A | 63 (22.99%) |
FLT3-TKD | 77 (28.1%) |
FLT3-ITD | 68 (24.82%) |
IDH1 | 28 (10.22%) |
IDH2 | 50 (18.25%) |
KRAS | 11 (4.01%) |
NPM1 | 83 (30.29%) |
RUNX1 | 39 (14.23%) |
TET2 | 62 (22.63%) |
TP53 | 24 (8.76%) |
WT1 | 9 (3.28%) |